DBVT
DBV Technologies S.A.
stockNASDAQADR
dbv technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly increasing in prevalence. food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. dbv technologies (incorporated in 2002) has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. the viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. the product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. dbv technologies is focusing on food allergies (milk and
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 10.55 | 2026-10-02 | -7.20% | -0.320 |
| 1M | 13.44 | 2026-09-09 | -27.16% | -0.432 |
| 3M | 16.08 | 2026-07-09 | -39.12% | 0.229 |
| 6M | 21.40 | 2026-04-09 | -54.25% | 0.801 |
| 1Y | 15.87 | 2025-10-09 | -38.31% | 0.872 |
| 2Y | 3.53 | 2024-10-09 | +177.73% | — |
| 5Y | 50.20 | 2021-10-08 | -80.50% | 0.462 |
DBV Technologies S.A. (NASDAQ:DBVT) stock price today is $9.79, and today's volume is 312,752. DBVT is up 2.513% today. The 30 day average volume is 365,446. DBVT market cap is $615.29M with 62.85M shares outstanding.